Assessing the Value of Avocados on Glycemic Control in Type 2 Diabetes

Recruiting now · Not applicable

Conditions studied: Diabetes Mellitus, Type 2, Insulin, Fructosamine, C-Reactive Protein, Glucose, Overweight and Obesity

In brief

The objective of this study is to assess the effects of Hass Avocados on glycemic control. The investigators hypothesize that Hass Avocado consumption will reduce fasting blood sugar compared to an isocaloric amount of other fruit during controlled feeding.

Key facts

Study ID: NCT05958368
Run by: Pennington Biomedical Research Center
People needed: 48
Starts: 2023-10-10
Expected to finish: 2026-12-15
Last updated by the study team: 2025-07-31

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Participant reported diagnosis of Type 2 diabetes
HbA1c between 5.7%-11% (inclusive) and / or fasting blood glucose of ≥ 100 mg/dL
BMI 27-50 kg/m2 (inclusive)
Age range - 18 - 65 years (inclusive)
On stable regimen of all medications (including diabetes) for at least 3 months (brief regimens of medications such as antibiotics, steroids, etc. are permitted)
Willing to follow all requirements of study protocol including blood draws
Under the care of a physician who will be responsible for managing the subject's diabetes
Willing to give release to provide their treating MD with information about the trial

You may not qualify if…

Not willing or unable to consume study foods including avocados
Participation in a weight control program within the past 3 months or weight loss of ≥ 5 kg in the previous 3 months
Taking prescription or OTC weight loss medications within last 4 weeks
History of a surgical procedure for weight loss in last 5 years (e.g. gastroplasty, gastric by-pass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve)
History of major surgery within three months of enrollment
Type 1 diabetes, insulin dependent type 2 diabetes, thiazolidinediones (including rosiglitazone and pioglitazone)
Renal insufficiency consisting of potassium over 5.5 (mmol/L) on a non-hemolyzed specimen, or a creatinine over 2.5 mg/dL
Bilirubin over 3 (mg/dL) or an albumin less than 3 (g/dL)
ALT > 3 (IU/L) times the upper limit of normal (normal range is 7-56)
Evidence of more than 1 severe hypoglycemic event (episode requiring emergency medical services) in the past 12 months, unless the participant's treating physician provides written clearance for participation.
Those on higher doses of diuretics (furosemide 40mg or higher or comparable)
Unstable heart disease (an ongoing workup or treatment for a cardiac symptom such as unstable angina, coronary ischemia)
Presence of implanted cardiac defibrillator
Blood pressure ≥180/100 mm Hg. If a potential participant has a BP above the inclusion criteria it is acceptable to re-test this potential participant within one week of the original test.
Thyroid disease for which the participant is untreated or has had treatment changed within the last 6 months. History of thyroid disease or current thyroid disease treated with a stable medication regimen for at least 6 months is acceptable
Uncontrolled gastrointestinal disorders including chronic malabsorptive conditions, peptic ulcer disease, Crohn's disease, chronic diarrhea, or active gallbladder disease
Current cancer or cancer treatment, or a history of cancer or cancer treatment within the last 3 years. Persons with successfully resected non-melanoma carcinoma of the skin may be enrolled.
Dementia, psychiatric illness, or substance abuse that may interfere with adherence (e.g., illness that is currently unstable or resistant to first-line therapy; substance abuse in the past year)
Women who are pregnant, lactating, trying to become pregnant or unwilling to use an effective means of birth control
Currently consuming >14 alcoholic drinks (1 drink = 12 fl oz beer, 4 fl oz wine or 1.5 fl oz liquor) per week and unwilling to stop intake during study participation
Participation in another clinical trial within 30 days prior to enrollment
Any other condition or factor which in the opinion of the study physician or investigator makes it inadvisable for the candidate to participate in the trial

Where it is running

Pennington Biomedical Research Center — Baton Rouge, Louisiana, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.